{
  "report_rows": [
    {
      "kpi": "Q2 adjusted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$5.82 vs. cons $5.71",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 revenue",
      "prediction": "BEAT",
      "answer": "pred ~$11.82B vs. cons $11.70B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 organic revenue growth",
      "prediction": "BEAT",
      "answer": "pred ~3.2% vs. cons 3.0%",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2026 revenue guidance midpoint",
      "prediction": "LOWER",
      "answer": "guide ~$47.55B vs. cons $47.70B (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 adjusted EPS guidance midpoint",
      "prediction": "UNCHANGED",
      "answer": "guide ~$24.90 vs. cons $24.88 (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 organic revenue growth guidance midpoint",
      "prediction": "UNCHANGED",
      "answer": "guide ~3.5% vs. cons 3.5% (FY2026)",
      "confidence": "HIGH"
    },
    {
      "kpi": "FY2026 adjusted operating-margin expansion",
      "prediction": "UNCHANGED",
      "answer": "guide ~70 bps vs. cons 70 bps (FY2026)",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": 3.2,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 1.6,
  "day5_path": "FADE",
  "day5_rationale": "A clean organic-growth acceleration and EPS beat should drive the initial gain, but a mechanically lower FY2026 revenue guide from the microbiology divestiture implies pred ~$0.10 of out-period EPS-estimate reductions vs. cons ~$0.00, causing revisions to temper the five-day move.",
  "day5_confidence": "MEDIUM"
}